Clinical Characteristics and Prognosis of HER2 Gene Phenotype in Patients with Non-Small Cell Lung Cancer

References

• Balata H, Fong KM, Hendriks LE, et al. Prevention and Early Detection for NSCLC: advances in Thoracic Oncology 2018. J Thorac Oncol. 2019;14(9):1513–1527. doi:10.1016/j.jtho.2019.06.011
   PubMed Web of Science ®Google Scholar
• Duma N, Santana-Davila R, Molina JR. Non-Small Cell Lung Cancer: epidemiology, Screening, Diagnosis, and Treatment. Mayo Clin Proc. 2019;94(8):1623–1640. doi:10.1016/j.mayocp.2019.01.013
   PubMed Web of Science ®Google Scholar
• Arbour KC, Riely GJ. Systemic therapy for locally advanced and metastatic non-small cell lung cancer: a review. JAMA. 2019;322(8):764–774. doi:10.1001/jama.2019.11058
   PubMed Web of Science ®Google Scholar
• Petrosyan F, Daw H, Haddad A, Spiro T, Sood R. Gene expression profiling for early-stage NSCLC. Am J Clin Oncol. 2015;38(1):103–107. doi:10.1097/COC.0b013e31828d95d8
   PubMed Web of Science ®Google Scholar
• Pasini A, Delmonte A, Tesei A, Calistri D, Giordano E. Targeting chromatin-mediated transcriptional control of gene expression in non-small cell lung cancer therapy: preclinical rationale and clinical results. Drugs. 2015;75(15):1757–1771. doi:10.1007/s40265-015-0461-3
   PubMed Web of Science ®Google Scholar
• Jebbink M, de Langen AJ, Boelens MC, Monkhorst K, Smit EF. The force of HER2 - A druggable target in NSCLC? Cancer Treat Rev. 2020;86:101996. doi:10.1016/j.ctrv.2020.101996
   PubMed Web of Science ®Google Scholar
• Baraibar I, Mezquita L, Gil-Bazo I, Planchard D. Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC. Crit Rev Oncol Hematol. 2020;148:102906. doi:10.1016/j.critrevonc.2020.102906
   PubMed Web of Science ®Google Scholar
• Masood A, Kancha RK, Subramanian J. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer harboring uncommon EGFR mutations: focus on Afatinib. Semin Oncol. 2019;46(3):271–283. doi:10.1053/j.seminoncol.2019.08.004
   PubMed Web of Science ®Google Scholar
• Postmus PE, Kerr KM, Oudkerk M, et al. ESMO Guidelines Committee. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv1–iv21. doi:10.1093/annonc/mdx222
   PubMed Web of Science ®Google Scholar
• Wakelee HA, Dahlberg SE, Brahmer JR, et al.; Eastern Cooperative Oncology Group. Differential effect of age on survival in advanced NSCLC in women versus men: analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab. Lung Cancer. 2012;76(3):410–415. doi:10.1016/j.lungcan.2011.12.006
   PubMed Web of Science ®Google Scholar
• Grimaldi S, Terroir M, Caramella C. Advances in oncological treatment: limitations of RECIST 1.1 criteria. Q J Nucl Med Mol Imaging. 2018;62(2):129–139. doi:10.23736/S1824-4785.17.03038-2
   PubMed Web of Science ®Google Scholar
• Gubens MA, Davies M. NCCN guidelines updates: new immunotherapy strategies for improving outcomes in non-small cell lung cancer. J Natl Compr Canc Netw. 2019;17(5.5):574–578. doi:10.6004/jnccn.2019.5005
   PubMed Web of Science ®Google Scholar
• Connell CM, Doherty GJ. Activating HER2 mutations as emerging targets in multiple solid cancers. ESMO Open. 2017;2(5):e000279. doi:10.1136/esmoopen-2017-000279
   PubMed Web of Science ®Google Scholar
• Lei YY, Huang JY, Zhao QR, et al. The clinicopathological parameters and prognostic significance of HER2 expression in gastric cancer patients: a meta-analysis of literature. World J Surg Oncol. 2017;15(1):68. doi:10.1186/s12957-017-1132-5
   PubMed Web of Science ®Google Scholar
• Iqbal N, Iqbal N. Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: overexpression and Therapeutic Implications. Mol Biol Int. 2014;2014:852748. doi:10.1155/2014/852748
   PubMedGoogle Scholar
• Siddiqui MR, Railkar R, Sanford T, et al. Targeting Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor 2 (HER2) Expressing Bladder Cancer Using Combination Photoimmunotherapy (PIT). Sci Rep. 2019;9(1):2084. doi:10.1038/s41598-019-38575-x
   PubMed Web of Science ®Google Scholar
• Palle J, Rochand A, Pernot S, Gallois C, Taïeb J, Zaanan A. Human Epidermal Growth Factor Receptor 2 (HER2) in Advanced Gastric Cancer: current Knowledge and Future Perspectives. Drugs. 2020;80(4):401–415. doi:10.1007/s40265-020-01272-5
   PubMed Web of Science ®Google Scholar
• Jang J, Son J, Park E, et al. Discovery of a highly potent and broadly effective epidermal growth factor receptor and HER2 exon 20 insertion mutant inhibitor. Angew Chem Int Ed Engl. 2018;57(36):11629–11633. doi:10.1002/anie.201805187
   PubMed Web of Science ®Google Scholar
• Arcila ME, Chaft JE, Nafa K, et al. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin Cancer Res. 2012;18(18):4910–4918. doi:10.1158/1078-0432.CCR-12-0912
   PubMed Web of Science ®Google Scholar
• De Grève J, Moran T, Graas MP, et al. Phase II study of Afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma. Lung Cancer. 2015;88(1):63–69. doi:10.1016/j.lungcan.2015.01.013
   PubMed Web of Science ®Google Scholar
• Dziadziuszko R, Smit EF, Dafni U, et al. Afatinib in NSCLC With HER2 Mutations: results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP). J Thorac Oncol. 2019;14(6):1086–1094. doi:10.1016/j.jtho.2019.02.017
   PubMed Web of Science ®Google Scholar
• Liu L, Shao X, Gao W, et al. The role of human epidermal growth factor receptor 2 as a prognostic factor in lung cancer: a meta-analysis of published data. J Thorac Oncol. 2010;5(12):1922–1932. doi:10.1097/JTO.0b013e3181f26266
   PubMed Web of Science ®Google Scholar